glp-1/gcgr dual agonist Possible mechanisms of glucagon‐like peptide‐1 receptor Activation of GCGR and GLP-1R

Liu DX, Zhao CS, Wei XN, Ma YP, Wu JK

Jia XT, Ye T, Yuan L, Zhang GJ, Liu ZQ, Di ZL, et al

Real-world users on tirzepatide lost approximately 12.4% of body weight at one year in a 2025 study, which is meaningfully higher than semaglutide alone

In a similar manner, Rosenstock et al

After two years (120 weeks), the patients retained roughly one-third of their original weight loss (5.6% of the original 17.3% loss)

POPULAR WEIGHT-LOSS DRUGS LINKED TO SUDDEN VISION LOSS "Most people who suffer from AMD have no treatment, so this is a great breakthrough in our search for new treatments," said Nick Bear, an ophthalmologist at the University of Liverpool in the U.K., who led the research